Clinical Trial Update: Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I) [Phase 3]

View source ↗

Summary

Phase 3 trial results for alirocumab in combination with other lipid-modifying therapy in hypercholesterolemia; the study completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• Praluent (alirocumab) (alirocumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Hypercholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2015-08-31